Welcome to Cynvec
Cynvec is an oncology focused biotechnology company developing its proprietary oncolytic Sindbis viral vector technology as a differentiated and transformational platform for the treatment of cancer.
Our cancer treatment platform, CYN, is designed to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. Our first product candidate, CYN-101, is a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer. It has been shown to selectively kill solid tumor cancer cells utilizing the viral vector’s natural binding and apoptotic characteristics together with its ability to activate the immune system.
To become the leader in developing and commercializing innovative cancer therapies based on our proprietary Sindbis viral vector technology.